Epigral

Epigral Receivables

The Accounts Receivable of Epigral (EPIGRAL.NS) as of Oct 21, 2026 is 2.32 B INR. In the previous year, Accounts Receivable was 1.79 B INR — a change of 29.97% (higher).

Receivables

2.32 BINR

YoY

29.97%

Last updated:

Accounts Receivable of Epigral is 2025 2.32 B INR. Accounts Receivable of Epigral was 2024 1.79 B INR. It decreases by 29.97% higher compared to the previous year.

The Epigral Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2021
1.24 B INR
Jan 1, 2022
2.56 B INR
Jan 1, 2023
1.66 B INR
Jan 1, 2024
1.79 B INR
Jan 1, 2025
2.32 B INR
The Epigral Receivables history
YEARReceivablesYoY
2.32 BINR+29.97%
1.79 BINR+7.47%
1.66 BINR-35.11%
2.56 BINR+107.10%
1.24 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Epigral Stock analysis

What does Epigral do? Meghmani Finechem Ltd. generates revenue through the manufacturing and sale of chemical products including chlor alkali derivatives, CPVC resin, caustic soda, caustic potash, chlorine, hydrogen, chloromethanes, and hydrogen peroxide. The company serves industries such as alumina, textile, crop protection, refineries, pharmaceutical, paper & pulp, and soaps & detergent. Its subsidiary Meghmani Advanced Sciences Limited supports the business operations. The firm also trades agrochemical products to meet agricultural sector demands. The primary buyers of Meghmani Finechem's products are industrial clients across multiple sectors including textile, pharmaceutical, and crop protection. These customers rely on the company's chemical solutions for their production processes. The company's focus on chlor alkali and derivative manufacturing positions it as a key supplier in the chemical industry. Agrochemical trading complements its core chemical manufacturing business. Meghmani Finechem Ltd. operates with a product portfolio centered around chlor alkali and its derivatives, which are essential for various industrial applications. The company's manufacturing capabilities include producing CPVC resin and other specialty chemicals. Its subsidiaries and product range cater to both industrial and agricultural markets. The firm's revenue streams are derived from direct sales to industrial clients and agrochemical trading activities. Epigral is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Epigral stock

Accounts Receivable of Epigral is 2.32 B INR in 2025.

Accounts Receivable of Epigral changed from 1.79 B INR to 2.32 B INR, representing a 29.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Epigral since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Epigral historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Epigral

All Key Metrics — Epigral